April 17, 2024

Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

Transcriptomic subtyping holds promise for personalized therapy in extensive-stage small cell lung cancer (ES-SCLC). In this study, we aimed to assess intratumoral transcriptomic subtype diversity and to identify biomarkers of long-term chemoimmunotherapy benefit in human ES-SCLC.

AI에게 질문

Bookmark

Cite This Study

Peressini et al. (Wed,) studied this question.

synapsesocial.com/papers/68e6eaccb6db643587665edc https://doi.org/https://doi.org/10.1158/1078-0432.ccr-24-0104

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation2023 · 87 citations
2A membrane-associated MHC-I inhibitory axis for cancer immune evasion2023 · 191 citations
3IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade2017 · 3,882 citations
41532P Phase IIIb study of durvalumab plus platinum-etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Preliminary efficacy results2022 · 4 citations
5Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN2022 · 324 citations

AI에게 질문

Bookmark